• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    $QDEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CTLT alert in real time by email

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board

    QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/

    R. Scott Huennekens (Photo: Business Wire)

    R. Scott Huennekens (Photo: Business Wire)

    These appointments align with QuidelOrtho's commitment to maintaining a strong, independent Board with the right mix of expertise and experience. These appointments are the culmination of a comprehensive search led by the Board's Nominating and Corporate Governance Committee and supported by an independent executive search firm.

    "We are excited to welcome John and Scott to our Board," said Kenneth F. Buechler, Ph.D., Chairman of the Board. "They bring proven track records of growth and value creation as CEOs and board members of healthcare, biopharma and MedTech companies. We are confident they will be significantly additive to the Board as we work with management to continue their positive momentum in executing QuidelOrtho's growth and transformation plans and in creating further shareholder value."

    "I believe QuidelOrtho's best days lie ahead as we strengthen our leadership team and Board. Both John and Scott bring valuable global experience, diverse expertise and a broad perspective that will be assets to the Company," said Brian J. Blaser, President and CEO, QuidelOrtho. "I look forward to benefiting from their guidance and partnership as we execute our transformational strategy, deliver enhanced financial results and bring forth innovative technologies that raise the performance of diagnostic testing and produce better patient outcomes."

    As a former CEO and board Chair, Mr. Chiminski brings a diversified medical diagnostics and pharmaceutical background, which includes operations leadership, product development and services, and a strong track record of growing global businesses. He served as CEO of Catalent (NYSE:CTLT) from 2009 to 2022, assumed the title of Chair of its board of directors in 2016, and served as Executive Chair from 2022 to 2023. He was instrumental in establishing Catalent as a standalone public company after its carve-out from Cardinal Health and transforming the company into a market leader in biopharma services. Prior to that, Mr. Chiminski spent more than 20 years with GE Healthcare in roles of increasing responsibility, ultimately serving as President and CEO of GE Medical Diagnostics, a global business with $1.9 billion in sales.

    Mr. Huennekens is a successful MedTech CEO, Chair, board member, entrepreneur and investor and has been involved in over 20 startups and public companies. He served as Chair, President and CEO of Verb Surgical, an independent surgical technology start-up jointly formed by Google and Johnson & Johnson, from 2015 to 2019. Prior to Verb Surgical, he was President and CEO at Volcano Corporation, a leader in minimally invasive therapy guidance in interventional cardiology, and prior to that, President and CEO at Digirad Corporation, a coronary imaging solutions provider. Previously, Mr. Huennekens held various leadership positions at Baxter Healthcare, Birtcher Medical Systems and Deloitte and Touche. He currently serves as Chair of the board of directors of Envista Holdings (NYSE:NVST) and as Chair of the board of directors of Hyperfine (NASDAQ:HYPR).

    As previously announced, James R. Prutow and Robert R. Schmidt resigned from the Board, effective November 21, 2024, in conjunction with the closing of the secondary offering of QuidelOrtho common stock by The Carlyle Group. With the appointments of Messrs. Chiminski and Huennekens, the Board will comprise 11 directors, 10 of whom are independent.

    Dr. Buechler added, "On behalf of the Board, I also want to acknowledge James and Robert for their insights and contributions. We thank them for their service to the Company."

    QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

    About QuidelOrtho Corporation

    QuidelOrtho Corporation (NASDAQ:QDEL) is a world leader in in-vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

    Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

    Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects, and a more informed path is illuminated for each of us.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241210769572/en/

    Get the next $CTLT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTLT
    $HYPR
    $NVST
    $QDEL

    CompanyDatePrice TargetRatingAnalyst
    Envista Holdings Corporation
    $NVST
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    QuidelOrtho Corporation
    $QDEL
    5/8/2025$44.00Hold → Buy
    Jefferies
    QuidelOrtho Corporation
    $QDEL
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    QuidelOrtho Corporation
    $QDEL
    12/10/2024$43.00Hold
    Jefferies
    Envista Holdings Corporation
    $NVST
    12/4/2024$20.00Underperform
    Mizuho
    Envista Holdings Corporation
    $NVST
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    Envista Holdings Corporation
    $NVST
    10/8/2024$20.00Equal Weight
    Wells Fargo
    QuidelOrtho Corporation
    $QDEL
    9/19/2024$42.00 → $50.00Neutral
    UBS
    More analyst ratings

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast

      Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments SAN DIEGO, July 24, 2025 /PRNewswire/ -- In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between life and death. But with the rise of counterfeit medications and drug combinations that are more potent and less predictable, emergency departments must adapt faster than ever. QuidelOrtho Science Bytes Episode 49 "How Urgent Diagnostic Testing

      7/24/25 9:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Hyperfine Swoop® AI-Powered Portable MRI System Showcased in Clinical Studies Designed to Broaden Access to Dementia Care

      New dementia study actively enrolling and new data to be presented at the 2025 Alzheimer's Association International Conference. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced two significant advancements highlighting the potential of its innovative MRI technology to expand dementia screening, enhance monitoring, and improve care. Globally, over 57 million people live with dementia, with Alzheimer's disease accounting for 60–80% of cases (Centers for Disease Control, World Health Organization). Limited access to conventio

      7/24/25 8:15:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Begins Commercial Launch of Optive AI™ Software, Bringing Substantially Improved Image Quality to the Installed Base of Swoop® Systems

      Optive AI™ software has now been installed in an initial set of hospitals and neurology offices across the U.S., marking the beginning of expanded access to transformative, AI-powered image quality from portable, ultra-low-field MRI systems. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the commercial launch of the Optive AI™ software for existing Swoop® system customers. Optive AI™ software, which also powers the transformative image quality of the next-generation Swoop® system, is now commercially available to customers

      7/23/25 8:15:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buechler Kenneth F exercised 9,215 shares at a strike of $15.74, increasing direct ownership by 10% to 101,921 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      7/17/25 4:09:04 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Pierce James Andrew was granted 9,155 shares (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      7/16/25 4:17:26 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Pierce James Andrew

      3 - Envista Holdings Corp (0001757073) (Issuer)

      7/16/25 4:15:51 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Envista upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

      5/27/25 9:05:49 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • QuidelOrtho upgraded by Jefferies with a new price target

      Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

      5/8/25 9:44:58 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho upgraded by Citigroup with a new price target

      Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

      12/11/24 8:21:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CTLT
    $HYPR
    $NVST
    $QDEL
    SEC Filings

    See more
    • Envista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Envista Holdings Corp (0001757073) (Filer)

      7/16/25 4:12:48 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SCHEDULE 13G filed by Envista Holdings Corporation

      SCHEDULE 13G - Envista Holdings Corp (0001757073) (Subject)

      7/15/25 4:03:16 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by QuidelOrtho Corporation

      SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      7/9/25 4:12:22 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      12/13/24 4:12:57 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/14/24 4:40:20 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/13/24 6:01:10 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Catalent Announces New Board Appointments

      Adds three new directors with deep expertise across biopharma and life sciences Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings' ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said "I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring

      2/20/25 9:00:00 AM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lennox International Set to Join S&P 500 and BILL Holdings to Join S&P MidCap 400

      NEW YORK, Dec. 18, 2024 /PRNewswire/ -- S&P MidCap 400 constituent Lennox International Inc. (NYSE:LII) will replace Catalent Inc. (NYSE:CTLT) in the S&P 500, and BILL Holdings Inc. (NYSE:BILL) will replace Lennox International in the S&P MidCap 400 effective prior to the opening of trading on Monday, December 23. Novo Holdings A/S has acquired Catalent in a deal that closed today, December 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector Dec 23, 2024 S&P 500 Addition Lennox International LII Industrials Dec 23, 2024 S&P 500 Deletion Catalent CTLT Health

      12/18/24 5:46:00 PM ET
      $BILL
      $CTLT
      $LII
      $SPGI
      EDP Services
      Technology
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Financials

    Live finance-specific insights

    See more
    • QuidelOrtho to Report Second Quarter 2025 Financial Results

      SAN DIEGO, July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested

      7/22/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Envista Schedules Second Quarter 2025 Earnings Call

      BREA, Calif., July 9, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2025 on Thursday, July 31, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation. You can access the conference call by diali

      7/9/25 4:10:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

      ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

      6/3/25 4:10:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CTLT
    $HYPR
    $NVST
    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      12/6/24 10:11:24 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

      SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

      11/21/24 5:10:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalent Inc.

      SC 13G/A - Catalent, Inc. (0001596783) (Subject)

      11/14/24 4:35:03 PM ET
      $CTLT
      Biotechnology: Pharmaceutical Preparations
      Health Care